ChemoCare Roadmap
2017

Prepared for: Customer Document
Prepared by: CIS Oncology Ltd
Date: March 2017
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tony Pegg</td>
<td>CEO</td>
<td>Signature</td>
<td>08/05/2017</td>
</tr>
</tbody>
</table>
## Contents

1. Introduction .................................................................................................................. 1
2. Description of New Functionality .................................................................................. 2
1 Introduction

The purpose of this document is to provide customers with an overview of the development strategy for ChemoCare over the next two to three years. The ChemoCare roadmap is developed in response to customer requests, strategic changes in service delivery defined by national directives and legal, safety and data mandates. Prioritisation of development effort is discussed with the ChemoCare Advisory Group who comprise of expert users from the three key disciplines and who represent their profession’s view of the development requirement. In describing the overview of the development strategy only major functional changes are included.

The developments presented in this document represent the current product plans and can be subject to change.
2 Description of New Functionality

- **Patient Access Controls**
  Two new security features limit a user’s access to a defined set of patients. Limits can be set so that users can only view patient records assigned to the location they are logged into and/or limited to patients whose managing consultant is defined in their user account.

- **Blueteq Interface**
  This feature provides the ability to set up a drug in a regimen that is defined as a CDF drug. When a regimen with a CDF drug is allocated in the system, ChemoCare will use the Blueteq interface to check for a CDF authorisation. The users will be warned until an authorisation is found. The authorisation stamp is stored as a treatment note and can be viewed by users with access to view annotations.

- **Electronic Prescription Transfer**
  This feature enables prescriptions to be transferred from one ChemoCare system to another from where the prescription can be dispensed and if required administered. When treatment is delivered in the system that has received the prescription a treatment given record is sent back to the system that issued the prescription.

- **Prescription Transfer Module**
  This module sits outside ChemoCare and monitors prescriptions to be transferred to other systems. This module enables the NHS to quickly see which prescriptions are currently transferred, manage the transfer and any prescription modifications. This module is also used with the receiving ChemoCare and is monitoring prescriptions transferred into ChemoCare.

- **Product logistics Module**
  The proposed product logistics module functionality is name we have given to a group of functions that are designed to assist pharmacy in managing and tracking the supply of drugs to the oncology service. Pharmacy Review will provide a dedicated workspace where prescription checks and drug supply can be managed.
  The main enhancements will include:
  - A dispensing list for oral drugs and the electronic registration of the dispensing process
  - An enhanced worksheet list that support enhanced tracking during the manufacturing and supply process. In addition the list will have improved sorting and filtering capabilities to support batch production of drugs.
  - The potential to transit electronic orders

- **Dose Schedule Enhancements**
  This enhancement enables users to predefine complex dose schedules that can be selected into cycles at configuration and can be selected by prescribers at the
point of prescribing to simplify the prescribing of complex dose schedules. This
dose scheduling will enable the potential to alert patients when doses are due.

- **Synchronised Protocols**
  This enhancement enables protocols to be configured with concurrent cycles in
  addition to the current capability where sequential cycles can be prescribed. This
  feature is designed to simplify the management of complex prescriptions with
  concurrent protocols that may require deferral as a whole.

- **Intrathecal List**
  This functionality is a group of additional system controls to enable users to more
  easily support compliance with the requirements of HSC 2008/001. This
  development builds on the existing functionality to support intrathecal prescribing
  requirements.

- **Parent App (Paediatrics)**
  This feature will enable parents to communicate with and view their child’s record
  in ChemoCare

- **Offline Working**
  This feature enables users to use ChemoCare from mobile devices when they
  are not connected to the ChemoCare database and to update ChemoCare when
  the mobile device is able to connect to the ChemoCare database. This
  development will enable electronic registration of information in ChemoCare in
  the community when connection to the internet is not possible.